

### Remarks

Please enter the above amendments prior to sustentative examination. Upon entry of the above amendments, this application will contain claims 1-24 pending and under consideration. It is believed that the claims are patentable. Applicants respectfully request timely examination of this application leading to allowance of all claims.

Claim 1 has been amended to delete reference to a “solvate” of the compound of formula 1. In addition the following minor typographical errors have been corrected: on line 1 of the R<sup>1</sup> group listing hydrogen has been added (for support see claim 2); on line 6 of the R<sup>1</sup> group listing -OC<sub>2</sub>-C<sub>6</sub>cyano has been corrected to -OC<sub>2</sub>-C<sub>6</sub>alkylcyano; on line 8 of the R<sup>9</sup> Markush group listing “alkynylaryl” has been corrected as --alkynylaryl--; on line 10 of the R<sup>9</sup> group listing --C<sub>1</sub>-C<sub>6</sub>alkylCO<sub>2</sub>R<sup>11</sup>-- added (for support see claim 3, line 7).

Claim 2 has been amended by deleting the term “alkyl” on line 7<sup>1</sup> and replacing “C<sub>0</sub>-C<sub>3</sub>alkylCONH<sub>2</sub>” with -- -CONH<sub>2</sub> -- in the penultimate line to conform with the group listing for R<sup>1</sup> of claim 1.

Claim 3 on line 4 “alkylamine” has been replaced with --alkylamine--.

Claim 9 has been amended by inserting “the” in the penultimate line to correct a minor typographical error.

Claim 10 has been amended beginning on the 5<sup>th</sup> line after the structures by deleting “C(O) C<sub>1</sub>-C<sub>3</sub> alkyl, C(O) C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>1</sub>-C<sub>3</sub> alkylCONR<sup>7</sup>R<sup>8</sup>, C<sub>1</sub>-C<sub>3</sub> alkylcyano, C<sub>1</sub>-C<sub>3</sub> alkylCO<sub>2</sub>R<sup>11</sup>, C<sub>1</sub>-C<sub>3</sub> and replacing “alkylNR<sup>7</sup>R<sup>8</sup>” with --C<sub>1</sub>-C<sub>3</sub> alkylamine-- to conform to the listing in claim 1.

Claims 2-13, 15 18, 21 have been amended to recite a compound or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof.

Claims 15-17, and 19 have been amended to depend from claim 1 and by deleting reference to “solvates”. In addition claims 16, 17, and 20 have been amended by deleting the term “preventing”.

Claim 22 has been canceled.

New Claims 23 and 24 have been added. Support for these claims can be found in the published PCT application on page 3 lines 1-10, and page 10, lines 5-14 *inter alia*.

---

<sup>1</sup> In reference to the published PCT application, publication no. WO 2005/097805.

It is believed that these amendments do not add new matter. The Examiner is invited to contact the undersigned attorney by telephone if there are any questions about this Response or other issues that may be resolved in that fashion.

Respectfully submitted,

/James B. Myers/

James B. Myers, Ph.D.  
Attorney for Applicants  
Registration No. 42,021  
Phone: 317-276-0755

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

September 8, 2006